Aarti Pharmalabs — 360° view

Aarti Pharmalabs, a company in the Pharmaceuticals industry, reported revenue of ₹610 crore and net profit of ₹71 crore for the September 2026 quarter.

Aarti Pharmalabs (NSE: AARTIPHARM) closed at ₹990.70 on 20 Nov 2026, up 39.0% over the past year. Its market capitalisation is ₹8,984 crore and it trades at 34.5 times earnings.

Share price
₹990.70 (20 Nov 2026)
Market cap
₹8,984 Cr (20 Nov 2026)
P/E
34.51 (20 Nov 2026)
Revenue
₹610 Cr (September 2026 quarter)
Net profit
₹71 Cr (September 2026 quarter)
ROCE
10.7% (FY26)
ROE
8.59% (FY26)
Book value
₹249 (FY26)
Dividend yield
0.35% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,047.25 / ₹585.00 (20 Nov 2026)
1-year return
39.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: AARTIPHARM

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.